REVELATION BIOSCIENCES, INC. (REVB) - Dilution Analysis

10-Q filing | 3.9M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 4,272,500 shares of common stock by the selling stockholders to be issued upon the exercise of common stock purchase warrants.

10-Q filing | 5.9M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 13,065,000 shares of common stock by the selling stockholders to be issued upon the exercise of common stock purchase warrants.

8-K filing: Revelation Biosciences, Inc. entered into warrant exercise inducement offer letters with certain holders to exercise existing warrants for shares of common stock in exchange for new common stock warrants, resulting in gross proceeds of approximately $9.6 million. ($9.6M proceeds)

8-K filing: Stock split 1-for-3 | Outstanding: 963,796 → 1,534,599

8-K filing: Revelation Biosciences, Inc. completed a public offering on May 29, 2025, selling 675,000 shares of common stock and pre-funded warrants to purchase 2,965,000 shares of common stock, along with warrants to purchase up to 14,560,000 shares of common stock, resulting in gross proceeds of approximately $4.0 million. ($12.0M proceeds)

S-1/A filing: Revelation Biosciences, Inc. is offering shares of common stock and warrants.

S-1 filing: This is an S-1 filing for Revelation Biosciences, Inc. involving the offering of common stock and warrants.

10-Q filing | 1.0M shares outstanding

10-K filing | 0.9M shares outstanding

8-K filing: Stock split 1-for-16 | Outstanding: 8,356,495 → 522,281

S-3/A filing: This prospectus relates to the resale of up to 14,224,140 shares of common stock by the selling stockholders to be issued upon the exercise of common stock purchase warrants.

S-3 filing: This prospectus relates to the resale of up to 14,224,140 shares of common stock to be issued upon the exercise of common stock purchase warrants.

8-K filing: Revelation Biosciences, Inc. issued new Class F and Class G Common Stock Warrants in exchange for the exercise of existing Class E Common Stock Warrants, with gross proceeds of approximately $4.1 million. ($4.1M proceeds)

8-K filing: Revelation Biosciences, Inc. entered into warrant exercise inducement offer letters with certain holders of its existing Class E Common Stock Warrants to exercise their warrants at an exercise price of $1.00 per share, in exchange for the Company's agreement to issue new Class F and Class G Common Stock Warrants. ($4.1M proceeds)

10-Q filing | 4.3M shares outstanding

S-3 filing: This S-3 filing is for the resale of up to 5,096,120 shares of common stock by selling stockholders, to be issued upon the exercise of common stock purchase warrants.

8-K filing: Revelation Biosciences, Inc. entered into warrant exercise inducement offer letters with certain holders to exercise their existing Class D Common Stock Warrants for 2,548,060 shares at $1.50 per share, issuing new warrants exercisable for up to 5,096,120 shares at $1.00 per share, with gross proceeds of approximately $3.8 million. ($3.8M proceeds)

10-Q filing | 1.6M shares outstanding

S-3 filing: Revelation Biosciences, Inc. is offering shares of its common stock, preferred stock and/or warrants to purchase common stock or preferred stock with a total value of up to $50,000,000 from time to time under this prospectus.

10-Q filing | 1.6M shares outstanding

10-K filing | 1.6M shares outstanding

8-K filing: Revelation Biosciences, Inc. closed a public offering on February 5, 2024, involving the sale of common stock, pre-funded warrants, and Class D common stock warrants, resulting in gross proceeds of approximately $6.2 million. ($6.2M proceeds)

S-1/A filing: This S-1/A filing includes the offering of common stock, pre-funded warrants, and Class D common stock warrants for Revelation Biosciences, Inc.

S-1/A filing: This is a best efforts public offering of 793,651 shares of our common stock, warrants to purchase up to 1,587,302 shares of our common stock, and the shares of common stock underlying the Class D Common Stock Warrants and pre-funded warrants.

8-K filing: Stock split 1-for-30 | Outstanding: 6,297,303 → 209,911

S-1 filing: Revelation Biosciences is conducting a best efforts public offering of common stock, warrants, and pre-funded warrants to fund the development of GEM-SSI, GEM-AKI and GEM-CKD and for working capital and general corporate purposes.

10-Q filing | 6.3M shares outstanding

10-Q filing | 5.8M shares outstanding

10-Q filing | 6.0M shares outstanding

10-K filing | 4.5M shares outstanding

8-K filing: Revelation Biosciences, Inc. closed a registered public offering on February 13, 2023, involving the sale of 2,888,600 shares of common stock and pre-funded warrants to purchase up to 336,400 shares, along with accompanying warrants to purchase up to 6,450,000 shares, at a combined price of $4.83 per share/warrant or $4.8299 per pre-funded warrant/warrant, resulting in gross proceeds of approximately $15.6 million. ($15.57M proceeds)

S-1/A filing: Revelation Biosciences, Inc. is offering 1,326,531 shares of common stock, warrants to purchase up to 2,653,062 shares of common stock, and pre-funded warrants to purchase up to 1,326,531 shares of common stock.

S-1/A filing: Revelation Biosciences, Inc. is offering 1,326,531 shares of common stock, warrants to purchase up to 2,653,062 shares of common stock, and pre-funded warrants to purchase up to 1,326,531 shares of common stock in a best efforts public offering.

8-K filing: Stock split 1-for-35 | Outstanding: 23,536,070 → 672,460

8-K filing: Revelation Biosciences, Inc. sold one share of Series A Preferred Stock to its CEO, James Rolke, for $5,000.00 in cash on December 19, 2022. ($0.01M proceeds)

S-1 filing: Revelation Biosciences, Inc. is offering 34,482,759 shares of common stock, warrants to purchase up to 68,965,518 shares of common stock, and pre-funded warrants to purchase up to 34,482,759 shares of common stock in a best efforts public offering.

S-1/A filing: Revelation Biosciences, Inc. is offering 34,482,759 shares of common stock, warrants to purchase up to 34,482,759 shares of common stock, pre-funded warrants to purchase up to 34,482,759 shares of common stock, and placement agent warrants to purchase up to 2,413,793 shares of common stock in a best efforts public offering.

10-Q filing | 23.5M shares outstanding

S-1 filing: Revelation Biosciences, Inc. is offering 18,248,175 shares of common stock, warrants to purchase up to 18,248,175 shares of common stock, pre-funded warrants to purchase up to 18,248,175 shares of common stock, and placement agent warrants to purchase up to 1,277,372 shares of common stock in a best efforts public offering.

10-Q filing | 23.4M shares outstanding

8-K filing: Revelation Biosciences, Inc. completed a public offering of 8,333,334 shares of common stock along with warrants to purchase up to 8,333,334 shares at a price of $0.60 per share and warrant, resulting in net proceeds of approximately $4.4 million. ($5.0M proceeds)

S-1/A filing: Revelation Biosciences, Inc. is filing an S-1/A form.

S-1/A filing: Revelation Biosciences, Inc. is offering 10,964,912 Shares of Common Stock, new common stock warrants to purchase up to 10,964,912 shares of common stock, and pre-funded warrants to certain purchasers.

S-1/A filing: This is an S-1/A filing for Revelation Biosciences, Inc. It includes information about a previous offering of common stock, pre-funded warrants, and common warrants.

S-1 filing: This S-1 filing relates to the resale of 15,217,802 shares of common stock by selling stockholders.

10-Q filing | 15.1M shares outstanding

10-K filing | 15.1M shares outstanding

S-1 filing: This prospectus relates to the resale of shares of Common Stock of Revelation Biosciences, Inc. and shares of Common Stock issuable upon exercise of Common Stock Purchase Warrants held by the selling stockholder which were issued by the Company in a previous private placement transaction to the selling stockholder named herein.

8-K filing: Revelation Biosciences, Inc. completed a private placement issuing 1,293,126 shares of common stock, 1,293,541 pre-funded warrants, and 2,586,667 common warrants for gross proceeds of approximately $7.76 million. ($3.88M proceeds)

8-K filing: Petra entered into backstop agreements for up to $4.5 million of shares of its common stock and a forward share purchase agreement with Meteora, committing to purchase shares at $10.2031 per share, secured by $7,652,325 in escrow. ($7.65M proceeds)

10-Q filing | 9.1M shares outstanding

8-K filing: Petra Acquisition, Inc. entered into a merger agreement with Revelation Biosciences, Inc., where Petra will acquire all outstanding equity interests of Revelation for 10,500,000 shares of Petra Common Stock.

10-Q filing | 8.0M shares outstanding

10-Q filing | 8.0M shares outstanding

10-K filing | 9.1M shares outstanding

10-Q filing | 9.3M shares outstanding

8-K filing: Petra Acquisition, Inc. consummated an initial public offering of 7,000,000 units at $10.00 per unit, generating gross proceeds of $70,000,000, and completed private sales of 3,150,000 private warrants at $1.00 per warrant, generating gross proceeds of $3,150,000. ($76.01M proceeds)

8-K filing: Petra Acquisition, Inc. completed its IPO of 7,000,000 units at $10.00 per unit, generating gross proceeds of $70,000,000, and also completed the private sale of 3,150,000 warrants to the Sponsor at $1.00 per warrant, generating gross proceeds of $3,150,000. ($73.15M proceeds)

S-1/A filing: S-1/A filing for a firm commitment offering of common stock, with LifeSci Capital LLC and Ladenburg Thalmann as joint book-running managers. The offering will deposit $75,750,000 (or $87,112,500 if the over-allotment option is exercised in full) or $10.10 per unit into a trust account.

S-1/A filing: An aggregate of $75,750,000 will be deposited into a U.S.-based trust account at $10.10 per unit.

S-1/A filing: S-1/A filing for a firm commitment basis offering with LifeSci Capital LLC and Ladenburg Thalmann as joint book-running managers. An aggregate of $125,000,000 (or $143,750,000 if the over-allotment option is exercised in full) or $10.00 per unit sold to the public in this offering will be deposited into a U.S.-based trust account.

S-1/A filing: S-1/A filing for a unit offering with LifeSci Capital LLC and Ladenburg Thalmann as joint book-running managers.

S-1 filing: S-1 filing for an offering with a proposed amount of $125,000,000, or $143,750,000 if the over-allotment option is exercised in full, at $10.00 per unit.